Article ID Journal Published Year Pages File Type
5701938 Journal of Thoracic Oncology 2017 12 Pages PDF
Abstract
A potential mechanism of acquired resistance to osimertinib in patients with T790M is through the BRAF pathway. Simultaneous blockade of the BRAF and EGFR had a significant inhibitory effect.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib
Authors
, , , , , , , , , , ,